SciBase AB attracts SEK 30 millions in new issue

STOCKHOLM, Sweden - 1 February, 2005 : Swedestart Life Science KB, managed/advised by CapMan, and SEB Företagsinvest invest together SEK 30 million in Swedish medtech company SciBase AB. The investment in SciBase will finance the pre-marketing development and launch of the initial product for diagnosing of cancers in the skin.

New CEO for the company is Christer Wallin. Mr Wallin's previous positions include CEO of NGM listed Biolight.

SciBase AB is a medtech company, founded in 1998 by Associate Professor Stig Ollmar. The company is specialized in determining malignancies in the skin by use of electric impedance. The first product is a prognostic instrument for determining cancers in the skin as melanoma, squamous cell carcinoma and basal cell cancer. The main markets for the company will be Europe and US. The company is based in Stockholm.

The chairman of the board, lawyer Jonas Bratt, says "With great satisfaction I have followed the R&D efforts of this company since its inception. That such competent investors as CapMan and SEB now make their entrance confirm that the Company is, and always was, on the right track"

- SciBase is a perfect example of what kind of companies CapMan likes to be involved in emphasizes Johan Bennarsten, Investment Manager at CapMan. "The company develops a unique product targeting a big clinical need and health-economic problem. Managing the patients with melanoma problem requires huge resources and the market opportunity is estimated to several billion SEK".

Viktor Drvota, business development life science at SEB Företagsinvest, comments the deal as "a very interesting business opportunity in a company with a unique technology for diagnosing malignant melanoma". SciBase has discovered a new principle to differentiate skin cancer from harmless spots without the need for operation.

For further information
CEO Christer Wallin, +46 702 198 580
Dr Johan Bennarsten, Investment Manager CapMan Life Science, +46 8 5458 5472
Dr Viktor Drvota, business development life science at SEB Företagsinvest, tel. +46 8 763 79 00 (operator)

SciBase AB
SciBase AB is a medical technology company, founded in 1998. The company is developing instrumentation for non-invasive diagnostics and monitoring of tissue alterations and different kinds of skin cancer. The instrument is utilizing a proprietary technology that has been developed at Karolinska Institutet by Stig Ollmar, the founder of the company. The technology is based on depth selective electrical impedance spectroscopy. The company has 3 employees and is based at Novum Research Park, Karolinska University Hospital in Huddinge. www.scibase.se.

CapMan Group
CapMan is one of the leading private equity investors in the Nordic countries and specializes in mid-sized buyouts in various industry sectors, technology investments in IT and

telecommunications and investments in life science companies. CapMan team comprises of more than 80 people in Helsinki, Stockholm, Copenhagen and Oslo. CapMan manages/ advises funds with approximately EUR 1.83 billion in total capital of which approx. EUR 573 million is managed by affiliated company Access Capital Partners, which invests in European private equity funds. To date, funds managed by CapMan have invested in 145 companies in the Nordic countries and exited from 66 companies. The latest investments are made in Swedish Gammadata AB, Finnish Tokmanni Oy, Norwegian Locus AS and Danish Anhydro Group. CapMan Plc is listed on the Main List of Helsinki Stock Exchange. www.capman.com.

SEB Företagsinvest
SEB Företagsinvest is the Venture Capital arm of Skandianviska Enskilda Banken (SEB). The business concept is to invest in venture capital and to provide competence and an extensive network of contacts for growth companies in Life Science and Technology in the Nordic area. Since start in 1995, SEB Företagsinvest has invested in more than 60 companies of which 25 have been exited. For more information, see www.seb.se/foretagsinvest.